Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era

Introduction High dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT) is a therapeutic option in follicular Lymphoma after first line treatment failure. The clinical characteristics and outcome of FL patients who relapsed after HDT+ASCT and therapeutic management in the rituximab era are not well known and may represent a difficult challenge.

Patients and Methods: The investigators conducted a retrospective analysis of FL patients who relapsed after HDT+ASCT in four French centers treated between 2000 and 2014. Clinical records were reviewed for clinical characteristics and treatment strategy at relapse. The investigators aimed to identify prognostic factors related to patient's outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Patient's Outcome Prognostic Factors Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Lyon Sud, Hematology department

Pierre-Bénite, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

they were older than 18 years
presented FL at diagnosis (Grade 1, 2, or 3a).
received high-dose therapy (HDT) with ASCT from 2000 to 2014

Exclusion criteria

they had already been treated with a 1st ASCT,
had a previous history of histological transformation before ASCT
if they were rituximab naive prior to ASCT.

Treatment and study plan

Primary outcomes

Survival after relapse (SAR) post ASCT in follicular lymphoma

Time frame: Year 6

Factors that predicted SAR

Secondary outcomes

Histological Transformation at relapse

Time frame: Year 6

A biopsy was performed at the first relapse or progression after ASCT.
treatment of relapse

Time frame: Year 6

Chemotherapy, radiotherapy…

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Important dates

Study start: 2017
Primary completion: 2017
Study completion: 2018
First posted: Sep 10, 2018
Registry last updated: Sep 10, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed